[{"id":"7a9cd977-e974-4fff-b14e-53d075776c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599556","created_at":"2021-01-19T20:29:53.326Z","updated_at":"2024-07-02T16:35:26.894Z","phase":"Phase 1","brief_title":"Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy","source_id_and_acronym":"NCT04599556","lead_sponsor":"Zhejiang University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD7 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-12-06"},{"id":"87757d5e-e4c2-487b-b78c-89fcbb239927","acronym":"","url":"https://clinicaltrials.gov/study/NCT05827835","created_at":"2023-04-25T14:03:31.508Z","updated_at":"2024-07-02T16:35:49.720Z","phase":"Phase 2","brief_title":"CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases","source_id_and_acronym":"NCT05827835","lead_sponsor":"Zhejiang University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD7 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2023","start_date":" 04/30/2023","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 04/25/2025","study_completion_date":" 04/25/2025","last_update_posted":"2023-04-25"},{"id":"8b3fce0e-07c5-4b21-88b3-6c8445090f12","acronym":"","url":"https://clinicaltrials.gov/study/NCT04823091","created_at":"2021-03-30T11:52:26.933Z","updated_at":"2024-07-02T16:36:15.265Z","phase":"Phase 1","brief_title":"Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies","source_id_and_acronym":"NCT04823091","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CD7 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 04/07/2024","study_completion_date":" 04/07/2024","last_update_posted":"2022-03-16"}]